Patents Assigned to HSC Research & Development Limited Partnership
-
Patent number: 8058243Abstract: A clonogenic neurosphere assay is described that carries out high throughput screens (HTS) to identify potent and/or selective modulators of proliferation, differentiation and/or renewal of neural precursor cells, neural progenitor cells and/or self-renewing and multipotent neural stem cells (NSCs). Compositions comprising the identified modulators and methods of using the modulators and compositions, in particular to treat neurological disorders (e.g. brain or CNS cancer) or damage are also disclosed.Type: GrantFiled: October 12, 2007Date of Patent: November 15, 2011Assignees: HSC Research and Development Limited Partnership, Mount Sinai HospitalInventors: Mike Tyers, Phedias Diamandis, Peter B. Dirks
-
Patent number: 7846679Abstract: The present invention describes the identification, isolation, cloning, and determination of the Alzheimer Related Membrane Protein (ARMP) gene on chromosome 14 and a related gene, E5-1, on chromosome 1. Normal and mutant copies of both genes are presented. Transcripts and products of these genes are useful in detecting and diagnosing Alzheimer's disease, developing therapeutics for treatment of Alzheimer's disease, as well as the isolation and manufacture of the protein and the construction of transgenic animals expressing the mutant genes.Type: GrantFiled: October 28, 2008Date of Patent: December 7, 2010Assignees: HSC Research and Development Limited Partnership, The Governing Council of the University of TorontoInventors: Peter H. St. George-Hyslop, Johanna M. Rommens, Paul E. Fraser
-
Patent number: 7838247Abstract: The present invention describes the identification, isolation, cloning, and determination of the Alzheimer Related Membrane Protein (ARMP) gene on chromosome 14 and a related gene, E5-1, on chromosome 1. Normal and mutant copies of both genes are presented. Transcripts and products of these genes are useful in detecting and diagnosing Alzheimer's disease, developing therapeutics for treatment of Alzheimer's disease, as well as the isolation and manufacture of the protein and the construction of transgenic animals expressing the mutant genes.Type: GrantFiled: August 20, 2007Date of Patent: November 23, 2010Assignees: HSC Research and Development Limited Partnership, The Governing Council of the University of TorontoInventors: Peter H. St. George-Hyslop, Johanna M. Rommens, Paul E. Fraser
-
Patent number: 7598419Abstract: Novel styrylacrylonitrile compounds which are useful in treating a variety of cell proliferative disorders such as cancer are disclosed.Type: GrantFiled: March 22, 2005Date of Patent: October 6, 2009Assignee: HSC Research and Development Limited PartnershipInventors: Chaim M. Roifman, Peter Demin, Andrew Freywald, Thomas Grunberger, Olga Rounova, Nigel Sharfe
-
Publication number: 20090191650Abstract: The present invention describes the identification, isolation, cloning, and determination of the Alzheimer Related Membrane Protein (ARMP) gene on chromosome 14 and a related gene, E5-1, on chromosome 1. Normal and mutant copies of both genes are presented. Transcripts and products of these genes are useful in detecting and diagnosing Alzheimer's disease, developing therapeutics for treatment of Alzheimer's disease, as well as the isolation and manufacture of the protein and the construction of transgenic animals expressing the mutant genes.Type: ApplicationFiled: October 28, 2008Publication date: July 30, 2009Applicants: The Governing Council of the University of Toronto, HSC Research and Development Limited PartnershipInventors: Peter H. St. George-Hyslop, Johanna M. Rommens, Paul E. Fraser
-
Patent number: 7560426Abstract: Pharmaceutical compositions comprising known verotoxins, particularly, verotoxin 1, have been found to be useful in the treatment of mammalian neoplasia, particularly, ovarian cancer and skin cancer. Surprisingly, although verotoxin 1 has previously been shown to have anti-neoplastic activity in vitro, non-lethal doses of verotoxin 1 have been shown to be therapeutically anti-neoplastic in vivo.Type: GrantFiled: March 12, 2007Date of Patent: July 14, 2009Assignees: HSC Research and Development Limited Partnership, Ontario Cancer InstituteInventors: Clifford A. Lingwood, Ruth Geva, legal representative, Leorah Kroyanker, legal representative, Richard Hill, Hannah Farkas-Himsley
-
Patent number: 7507798Abstract: The present invention describes the identification, isolation, cloning, and determination of the Alzheimer Related Membrane Protein (ARMP) gene on chromosome 14 and a related gene, E5-1, on chromosome 1. Normal and mutant copies of both genes are presented. Transcripts and products of these genes are useful in detecting and diagnosing Alzheimer's disease, developing therapeutics for treatment of Alzheimer's disease, as well as the isolation and manufacture of the protein and the construction of transgenic animals expressing the mutant genes.Type: GrantFiled: February 24, 2005Date of Patent: March 24, 2009Assignees: HSC Research and Development Limited Partnership, The Governing Council of the University of TorontoInventors: Peter H. St. George-Hyslop, Johanna M. Rommens, Paul E. Fraser
-
Publication number: 20090076019Abstract: A clonogenic neurosphere assay is described that carries out high throughput screens (HTS) to identify potent and/or selective modulators of proliferation, differentiation and/or renewal of neural precursor cells, neural progenitor cells and/or self-renewing and multipotent neural stem cells (NSCs). Compositions comprising the identified modulators and methods of using the modulators and compositions, in particular to treat neurological disorders (e.g. brain or CNS cancer) or damage are also disclosed.Type: ApplicationFiled: October 12, 2007Publication date: March 19, 2009Applicants: Mount Sinai Hospital, HSC Research and Development Limited PartnershipInventors: Mike Tyers, Phedias Diamandis, Peter B. Dirks
-
Publication number: 20070243612Abstract: Novel styrylacrylonitrile compounds which are useful in treating a variety of cell proliferative disorders such as cancer are disclosed.Type: ApplicationFiled: March 22, 2005Publication date: October 18, 2007Applicant: HSC Research and Development Limited PartnershipInventors: Chaim Roifman, Peter Demin, Andrew Freywald, Thomas Grunberger, Olga Rounova, Nigel Sharfe
-
Patent number: 7208468Abstract: Pharmaceutical compositions comprising known verotoxins, particularly, verotoxin 1, have been found to be useful in the treatment of mammalian neoplasia, particularly, ovarian cancer and skin cancer. Surprisingly, although verotoxin 1 has previously been shown to have anti-neoplastic activity in vitro, non-lethal doses of verotoxin 1 have been shown to be therapeutically anti-neoplastic in vivo.Type: GrantFiled: November 12, 2004Date of Patent: April 24, 2007Assignees: HSC Research and Development Limited Partnership, Ontario Cancer InstituteInventors: Clifford A. Lingwood, Ruth Geva, legal representative, Leorah Kroyanker, legal representative, Richard Hill, Hannah Farkas-Himsley, deceased
-
Patent number: 7118886Abstract: The present invention describes the identification, isolation and characterization of novel mammalian proteins encoded by the Ese1 and Ese2 genes which are involved in endocytosis, vesicular trafficking and regulation of the actin cytoskeleton. Transcripts and products of these genes are useful for detecting abnormal cellular endocytosis processes as well as for developing assay systems to find and elucidate further binding partners of the proteins, to develop therapeutics to alter/restore protein function and for the isolation and manufacture of Ese proteins.Type: GrantFiled: April 27, 1999Date of Patent: October 10, 2006Assignee: HSC Research and Development Limited PartnershipInventors: Sean E. Egan, Wei Wang, Ameet Sengar
-
Patent number: 7105636Abstract: A new family of proteins, the SARA proteins, has been identified. These proteins bind to receptor-regulated Smad proteins and modulate signal transduction by TGF?, activin and bone morphogenetic protein.Type: GrantFiled: July 20, 1999Date of Patent: September 12, 2006Assignee: HSC Research and Development Limited PartnershipInventor: Jeffrey L. Wrana
-
Patent number: 6998467Abstract: The present invention describes the identification, isolation, cloning, and determination of the Alzheimer Related Membrane Protein (ARMP) gene on chromosome 14 and a related gene, E5-1, on chromosome 1. Normal and mutant copies of both genes are presented. Transcripts and products of these genes are useful in detecting and diagnosing Alzheimer's disease, developing therapeutics for treatment of Alzheimer's disease, as well as the isolation and manufacture of the protein and the construction of transgenic animals expressing the mutant genes.Type: GrantFiled: October 12, 2000Date of Patent: February 14, 2006Assignees: The Hospital for Sick Children, HSC Research and Development Limited Partnership, The Governing Council of the University of TorontoInventors: Peter H. St. George-Hyslop, Johanna M. Rommens, Paul E. Fraser
-
Patent number: 6835710Abstract: Pharmaceutical compositions comprising known verotoxins, particularly, verotoxin 1, have been found to be useful in the treatment of mammalian neoplasia, particularly, ovarian cancer and skin cancer. Surprisingly, although verotoxin 1 has previously been shown to have anti-neoplastic activity in vitro, non-lethal doses of verotoxin 1 have been shown to be therapeutically anti-neoplastic in vivo.Type: GrantFiled: August 3, 2000Date of Patent: December 28, 2004Assignees: HSC Research & Development Limited Partnership, Ontario Cancer InstituteInventors: Clifford A. Lingwood, Hannah Farkas-Himsley, Richard Hill
-
Publication number: 20040209845Abstract: Novel styrylacrylonitrile compounds which are useful in treating a variety of cell proliferative disorders such as cancer are disclosed.Type: ApplicationFiled: March 17, 2004Publication date: October 21, 2004Applicant: HSC Research and Development Limited PartnershipInventors: Chaim M. Roifman, Thomas Grunberger, Olga Rounova, Demin Peter, Nigel Sharfe
-
Patent number: 6800659Abstract: Novel styrylacrylonitrile compounds which are useful in treating a variety of cell proliferative disorders such as cancer are disclosed.Type: GrantFiled: April 12, 2001Date of Patent: October 5, 2004Assignee: HSC Research and Development Limited PartnershipInventors: Chaim M. Roifman, Thomas Grunberger, Olga Rounova, Demin Peter, Nigel Sharfe
-
Patent number: 6765086Abstract: A polypeptide is provided that has a secondary structure characterized by at least three beta-sheet/beta-turn structures, and that is not a naturally occurring fibrous protein. Such polypeptides, illustrated by one modeled on elastin, are useful in prosthesis.Type: GrantFiled: September 28, 2001Date of Patent: July 20, 2004Assignees: Protein Specialties, Ltd., HSC Research & Development Limited PartnershipInventors: Aser Rothstein, Fred Keeley, Steven Rothstein
-
Patent number: 6696272Abstract: The invention relates to products and methods for medical treatment of Gaucher disease and, in particular, an improved Gcc DNA for insertion into any applicable expression vector for gene therapy treatment. The invention includes an isolated Gcc DNA molecule, wherein nucleic acid molecules have been modified at cryptic splice sites to prevent or decrease splicing of mRNA produced from the DNA molecule, while preserving the ability of the DNA to express functional Gcc polypeptides.Type: GrantFiled: June 2, 2000Date of Patent: February 24, 2004Assignee: HSC Research & Development Limited PartnershipInventors: Don J. Mahuran, Joe T. R. Clarke, John W. Callahan
-
Publication number: 20040006777Abstract: The invention provides a human gene encoding two new cytoplasmic phosphatases, Lyp1 and Lyp2, as well as the proteins and methods for preparing and using the described gene and proteins.Type: ApplicationFiled: December 3, 2002Publication date: January 8, 2004Applicant: HSC Research and Development Limited PartnershipInventor: Chaim M. Roifman
-
Patent number: 6562957Abstract: A method of diagnosing hereditary haemorrhagic telangiectasia (HHT) which includes the steps of: obtaining a sample of genomic DNA from a patient or fetus; and determining whether the DNA contains a mutation in a gene encoding endoglin, betaglycan, TGF-&bgr; type I receptor (RI), TGF-&bgr; type II receptor (RII), or TGF-&bgr;/activin type I receptor (TSR-I), such a mutation being an indication that the patient or fetus bears a gene making the patient or fetus susceptible to HHT.Type: GrantFiled: September 28, 1999Date of Patent: May 13, 2003Assignees: HSC Research & Development Limited Partnership, Duke UniversityInventors: Michelle Letarte, Douglas A. Marchuk, Kimberly McAllister